SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1552 5260 OR L773:1552 5279 "

Sökning: L773:1552 5260 OR L773:1552 5279

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Quaglia, Milena, et al. (författare)
  • Better Measurement for Improved Diagnosis and Management of Alzheimer's Disease : Update on the Empir Neuromet Project
  • 2018
  • Ingår i: Alzheimer's & Dementia. - 1552-5260 .- 1552-5279. ; 14, s. P759-P760
  • Tidskriftsartikel (övrigt vetenskapligt)abstract
    • The development of novel therapies for Alzheimer’s Disease (AD) is constrained by the lack of available methods for preclinical diagnosis, despite extensive research on biomarker identification. Here, we present an update of progress from EMPIR NeuroMET, a project combining diverse expertise from five National Measurement Institutes (NMIs), with clinicians and academics, to overcome limitations in measurement methods in neurodegenerative disease diagnosis and treatment.
  •  
2.
  • Babulal, Ganesh M, et al. (författare)
  • Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need.
  • 2019
  • Ingår i: Alzheimer's & Dementia. - 1552-5260 .- 1552-5279. ; 15:2, s. 292-312
  • Tidskriftsartikel (refereegranskat)abstract
    • Alzheimer's disease and related dementias (ADRDs) are a global crisis facing the aging population and society as a whole. With the numbers of people with ADRDs predicted to rise dramatically across the world, the scientific community can no longer neglect the need for research focusing on ADRDs among underrepresented ethnoracial diverse groups. The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART; alz.org/ISTAART) comprises a number of professional interest areas (PIAs), each focusing on a major scientific area associated with ADRDs. We leverage the expertise of the existing international cadre of ISTAART scientists and experts to synthesize a cross-PIA white paper that provides both a concise "state-of-the-science" report of ethnoracial factors across PIA foci and updated recommendations to address immediate needs to advance ADRD science across ethnoracial populations.
  •  
3.
  • Bateman, Daniel R., et al. (författare)
  • Agitation and impulsivity in mid and late life as possible riskmarkers for incident dementia
  • 2020
  • Ingår i: Alzheimer's & Dementia. - : Elsevier. - 1552-5260 .- 1552-5279. ; 6:1
  • Forskningsöversikt (refereegranskat)abstract
    • To identify knowledge gaps regarding new-onset agitation and impulsivity prior to onsetof cognitive impairment or dementia the International Society to Advance Alzheimer’sResearch and Treatment Neuropsychiatric Syndromes (NPS) Professional InterestAreaconducted a scoping review. Extending a series of reviews exploring the pre-dementiarisk syndrome Mild Behavioral Impairment (MBI), we focused on late-onset agitationand impulsivity (the MBI impulse dyscontrol domain) and risk of incident cognitivedecline and dementia. This scoping review of agitation and impulsivity pre-dementiasyndromes summarizes the current biomedical literature in terms of epidemiology,diagnosis andmeasurement, neurobiology, neuroimaging, biomarkers, course and prognosis,treatment, and ongoing clinical trials. Validations for pre-dementia scales suchas the MBI Checklist, and incorporation into longitudinal and intervention trials, areneeded to better understand impulse dyscontrol as a risk factor for mild cognitiveimpairment and dementia.
  •  
4.
  • Bell, Joanne, et al. (författare)
  • A novel BACE inhibitor (PF-05297909): : A two-part adaptive design to evaluate safety, pharmacokinetics and pharmacodynamics for modifying beta-amyloid in a first-in-human study
  • 2013
  • Ingår i: Alzheimer's & Dementia. - 1552-5260 .- 1552-5279. ; 9:4, s. P287-
  • Tidskriftsartikel (refereegranskat)abstract
    • BackgroundThe accumulation of amyloid beta (Aβ) peptides is believed to be a central contributor to the neurodegeneration seen in the Alzheimer's disease (AD) brain. Given the central role of Aβ42 in AD pathogenesis, a therapeutic strategy to lower central Aβ42 (and Aβ40) levels via inhibition of BACE was adopted in a first in human trial in a 2-part adaptive design.MethodsPart 1 evaluated PF-05297909 plasma PK and the PK/PD relationship for the reduction of plasma Aβ40, Aβ42 and AβX levels; Part 2 evaluated the exposure-response relationship between PF-05297909 and CSF levels of Aβ40, Aβ42 and AβX. Sufficient safety and tolerability, plasma exposure and reduction in plasma Aβ were necessary to initiate Part 2. Part 1 was a sequential parallel group dose escalation (25, 100, 250 and 325 mg) with n=8 (6:2, active:placebo) healthy volunteers (HV) in each cohort. Part 2 consisted of 3 cohorts of n=8 (6:2, active:placebo) HV. Doses selected for Part 2 started with the highest safe dose in Part 1 and then adapted for subsequent cohorts. The PK/PD relationship between PF-05297909 and Aβ42 was determined using a non-linear mixed effects (NLME) analysis. The doses for Part 2 - cohort 2 and 3 were to be chosen to improve the relative standard error in the estimate of the BACE IC50 as quantified by evaluating the determinant of the Fisher information matrix for the NLME model.ResultsPF-05297909 was well-tolerated. Reduction in plasma Aβ (Aβ40 and Aβ42) was exposure related with an apparent maximum at the 250 mg dose with a greater duration of activity at the 325 mg dose of PF-05297909. A 325 mg dose was selected for Part 2 - cohorts 1 and 2 without further cohorts being run, as stopping criteria for futility were met following analysis of cohort 2. A PK/PD relationship in CSF was not observed.ConclusionsThe adaptive designed PF-05297909 FIH study allowed efficient testing of safety and of the PK/PD relationship between PF-05297909 exposure and Aβ (Aβ40 and Aβ42). PF-05297909 was safe and well tolerated in HV at exposures tested. A robust effect on plasma Aβ did not translate to CSF pharmacodynamic effects.
  •  
5.
  • Benedict, Christian, et al. (författare)
  • Self-reported sleep disturbance is associated with Alzheimer's disease risk in men
  • 2015
  • Ingår i: Alzheimer's & Dementia. - 1552-5260 .- 1552-5279. ; 11:9, s. 1090-1097
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: To study the association between self-reported sleep disturbances and dementia risk.METHODS: Self-reported sleep disturbances and established risk factors for dementia were measured in men at ages 50 (n = 1574) and 70 (n = 1029) years. Dementia incidence was determined by reviewing their patient history between ages 50 and 90 years. In addition, plasma levels of β-amyloid (Aβ) peptides 1-40 and 1-42 were measured at ages 70, 77, and 82 years.RESULTS: Cox regression demonstrated that men with self-reported sleep disturbances had a higher risk of developing dementia (+33%) and Alzheimer's disease (AD, +51%) than men without self-reported sleep disturbances (both P < .05). Binary logistic regression showed the increased risk for both dementia (+114%) and AD (+192%) were highest when sleep disturbance was reported at age 70 years (both P < .001). No group differences were found in Aβ levels.CONCLUSION: Improving sleep quality may help reduce the neurodegenerative risk in older men.
  •  
6.
  • Bereczki, E., et al. (författare)
  • Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia
  • 2016
  • Ingår i: Alzheimer's & Dementia. - 1552-5260 .- 1552-5279. ; 12:11, s. 1149-1158
  • Tidskriftsartikel (refereegranskat)abstract
    • Introduction Our objective was to compare the levels of three synaptic proteins involved in different steps of the synaptic transmission: Rab3A, SNAP25, and neurogranin, in three common forms of dementia: Alzheimer's disease (AD), dementia with Lewy bodies (DLB), and Parkinson's disease dementia. Methods A total of 129 postmortem human brain samples were analyzed in brain regional specific manner exploring their associations with morphologic changes and cognitive decline. Results We have observed robust changes reflecting synaptic dysfunction in all studied dementia groups. There were significant associations between the rate of cognitive decline and decreased levels of Rab3 in DLB in the inferior parietal lobe and SNAP25 in AD in the prefrontal cortex. Of particular note, synaptic proteins significantly discriminated between dementia cases and controls with over 90% sensitivity and specificity. Discussion Our findings suggest that the proposition that synaptic markers can predict cognitive decline in AD, should be extended to Lewy body diseases. © 2016 The Alzheimer's Association
  •  
7.
  • Bos, I., et al. (författare)
  • Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum
  • 2019
  • Ingår i: Alzheimers & Dementia. - : Elsevier. - 1552-5260 .- 1552-5279. ; 15:5, s. 644-654
  • Tidskriftsartikel (refereegranskat)abstract
    • Introduction: We investigated relations between amyloid-beta (A beta) status, apolipoprotein E (APOE) e4, and cognition, with cerebrospinal fluid markers of neurogranin (Ng), neurofilament light (NFL), YKL-40, and total tau (T-tau). Methods: We included 770 individuals with normal cognition, mild cognitive impairment, and Alzheimer's disease (AD)-type dementia from the EMIF-AD Multimodal Biomarker Discovery study. We tested the association of Ng, NFL, YKL-40, and T-tau with A beta status (Ab beta- vs. A beta+), clinical diagnosis APOE epsilon 4 carriership, baseline cognition, and change in cognition. Results: Ng and T-tau distinguished between A beta+ from A beta- individuals in each clinical group, whereas NFL and YKL-40 were associated with A beta+ in nondemented individuals only. APOE epsilon 4 carriership did not influence NFL, Ng, and YKL-40 in A beta+ individuals. NFL was the best predictor of cognitive decline in A beta+ individuals across the cognitive spectrum. Discussion: Axonal degeneration, synaptic dysfunction, astroglial activation, and altered tau metabolism are involved already in preclinical AD. NFL may be a useful prognostic marker. (C) 2019 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
  •  
8.
  • Chouraki, V, et al. (författare)
  • Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study.
  • 2015
  • Ingår i: Alzheimer's & Dementia. - : Wiley. - 1552-5260 .- 1552-5279. ; 11:3
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Plasma amyloid-β (Aβ) peptide levels have been examined as a low-cost accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results have varied between studies. We reassessed these associations in one of the largest, prospective, community-based studies to date. METHODS: A total of 2189 dementia-free, Framingham Study participants aged >60 years (mean age, 72 ± 8 years; 56% women) had plasma Aβ1-42 and Aβ1-40 measured and were followed prospectively (mean, 7.6 ± 3.0 years) for dementia/AD. RESULTS: Increased plasma Aβ1-42 levels were associated with lower risk of dementia (Aβ1-42: hazard ratio [HR] = 0.80 [0.71‒0.90], P < .001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.86 [0.76‒0.98], P = .027) and AD (Aβ1-42: HR = 0.79 [0.69‒0.90], P < .001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.83 [0.72‒0.96], P = .012). CONCLUSION: Our results suggest that lower plasma Aβ levels are associated with risk of incident AD and dementia. They encourage further evaluation of plasma Aβ levels as a biomarker for risk of developing clinical AD and dementia. Copyright © 2014 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
  •  
9.
  • Ding, Mozhu, et al. (författare)
  • Tracing temporal trends in dementia incidence over 25 years in central Stockholm, Sweden
  • 2020
  • Ingår i: Alzheimer's & Dementia. - 1552-5260 .- 1552-5279. ; 16:5, s. 770-778
  • Tidskriftsartikel (refereegranskat)abstract
    • Introduction: Recent reports from high-income countries have suggested a declining incidence of dementia.Methods: Trends in dementia incidence over 25 years among people >= 75 years of age were examined using two population-based cohort studies: the Kungsholmen Project (KP, n = 1473, 1987-1998) and the Swedish National study on Aging and Care in Kungsholmen (SNAC-K, n = 1746, 2001-2013).Results: We identified 440 (29.9%) and 388 (22.2%) incident dementia cases in the KP and SNAC-K cohorts, respectively. The incidence of dementia declined by 30% (hazard ratio [HR] = 0.70; 95% confidence interval [CI] 0.61-0.80) during the second decade. Adjustment of education, psychosocial working conditions, lifestyle, and vascular diseases did not substantially change the results (HR = 0.77, 95% CI 0.65-0.90). This decline was observed particularly in women and people with elementary education.Discussion: Our study provides direct evidence of a declining trend in dementia incidence. Improved cognitive reserve and cardiovascular health could partially explain the decline.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (243)
konferensbidrag (21)
forskningsöversikt (9)
Typ av innehåll
refereegranskat (258)
övrigt vetenskapligt (15)
Författare/redaktör
Blennow, Kaj, 1958 (61)
Zetterberg, Henrik, ... (56)
Scheltens, P (30)
Hansson, Oskar (26)
Kivipelto, M (25)
Soininen, H (25)
visa fler...
Blennow, K (24)
Scheltens, Philip (24)
Visser, PJ (24)
Skoog, Ingmar, 1954 (23)
Soininen, Hilkka (22)
Winblad, B (21)
Tsolaki, M (20)
Blennow, Kaj (20)
Frisoni, GB (19)
Teunissen, Charlotte ... (18)
Molinuevo, JL (18)
Ossenkoppele, Rik (18)
Zetterberg, Henrik (18)
Zetterberg, H. (17)
Molinuevo, José Luis (17)
Wimo, A (17)
Schöll, Michael, 198 ... (16)
Tsolaki, Magda (15)
van der Flier, Wiesj ... (15)
Kivipelto, Miia (14)
Barkhof, F (14)
Lovestone, S (13)
Fratiglioni, L (13)
Nordberg, Agneta (13)
Frisoni, Giovanni B. (13)
Engelborghs, Sebasti ... (13)
Mattsson, Niklas (13)
Lleo, A (13)
Nordberg, A (12)
Shaw, Leslie M (12)
Engelborghs, S (12)
Rabinovici, Gil D (12)
Vandenberghe, R (11)
Barkhof, Frederik (11)
Frolich, L (11)
Jonsson, L. (10)
Jagust, William J. (10)
Skoog, I (10)
Fratiglioni, Laura (10)
Vellas, B (10)
Solomon, A (10)
Lleó, Alberto (10)
Trojanowski, John Q (10)
Hampel, H. (10)
visa färre...
Lärosäte
Göteborgs universitet (131)
Karolinska Institutet (100)
Lunds universitet (30)
Stockholms universitet (25)
Uppsala universitet (15)
Umeå universitet (11)
visa fler...
Luleå tekniska universitet (8)
Örebro universitet (7)
Linköpings universitet (5)
Linnéuniversitetet (5)
Jönköping University (3)
Södertörns högskola (3)
Gymnastik- och idrottshögskolan (2)
Röda Korsets Högskola (2)
Högskolan i Skövde (1)
RISE (1)
Karlstads universitet (1)
Ersta Sköndal Bräcke högskola (1)
visa färre...
Språk
Engelska (273)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (195)
Naturvetenskap (6)
Samhällsvetenskap (4)
Teknik (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy